CN113015543A - Pcsk9抑制剂用于降低心血管风险的用途 - Google Patents

Pcsk9抑制剂用于降低心血管风险的用途 Download PDF

Info

Publication number
CN113015543A
CN113015543A CN201980029013.2A CN201980029013A CN113015543A CN 113015543 A CN113015543 A CN 113015543A CN 201980029013 A CN201980029013 A CN 201980029013A CN 113015543 A CN113015543 A CN 113015543A
Authority
CN
China
Prior art keywords
patient
risk
fatal
cardiovascular
death
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201980029013.2A
Other languages
English (en)
Chinese (zh)
Inventor
G·施瓦茨
R·波尔迪
L·贝萨克
C·阿诺汀
W·萨西拉
P·斯泰格
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sanofi Biotechnology SAS
Regeneron Pharmaceuticals Inc
Original Assignee
Sanofi Biotechnology SAS
Regeneron Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Biotechnology SAS, Regeneron Pharmaceuticals Inc filed Critical Sanofi Biotechnology SAS
Publication of CN113015543A publication Critical patent/CN113015543A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/92—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving lipids, e.g. cholesterol, lipoproteins, or their receptors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/32—Cardiovascular disorders
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/32—Cardiovascular disorders
    • G01N2800/324—Coronary artery diseases, e.g. angina pectoris, myocardial infarction

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Genetics & Genomics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cardiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Endocrinology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
CN201980029013.2A 2018-03-06 2019-03-06 Pcsk9抑制剂用于降低心血管风险的用途 Pending CN113015543A (zh)

Applications Claiming Priority (35)

Application Number Priority Date Filing Date Title
US201862639407P 2018-03-06 2018-03-06
US62/639,407 2018-03-06
US201862640361P 2018-03-08 2018-03-08
US62/640,361 2018-03-08
US201862641082P 2018-03-09 2018-03-09
US62/641,082 2018-03-09
US201862641918P 2018-03-12 2018-03-12
US62/641,918 2018-03-12
US201862657495P 2018-04-13 2018-04-13
US62/657,495 2018-04-13
US201862683695P 2018-06-12 2018-06-12
US62/683,695 2018-06-12
US201862688622P 2018-06-22 2018-06-22
US62/688,622 2018-06-22
US201862717530P 2018-08-10 2018-08-10
US62/717,530 2018-08-10
US201862736284P 2018-09-25 2018-09-25
US62/736,284 2018-09-25
US201862744008P 2018-10-10 2018-10-10
US62/744,008 2018-10-10
US201862746319P 2018-10-16 2018-10-16
US62/746,319 2018-10-16
US201862770530P 2018-11-21 2018-11-21
US62/770,530 2018-11-21
US201862775219P 2018-12-04 2018-12-04
US62/775,219 2018-12-04
US201962797680P 2019-01-28 2019-01-28
US62/797,680 2019-01-28
US201962802545P 2019-02-07 2019-02-07
US62/802,545 2019-02-07
US201962806313P 2019-02-15 2019-02-15
US62/806,313 2019-02-15
EP19305247.9 2019-03-04
EP19305247 2019-03-04
PCT/US2019/021034 WO2019173530A1 (en) 2018-03-06 2019-03-06 Use of pcsk9 inhibitor for reducing cardiovascular risk

Publications (1)

Publication Number Publication Date
CN113015543A true CN113015543A (zh) 2021-06-22

Family

ID=66001316

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201980029013.2A Pending CN113015543A (zh) 2018-03-06 2019-03-06 Pcsk9抑制剂用于降低心血管风险的用途

Country Status (11)

Country Link
US (1) US20190292273A1 (https=)
EP (1) EP3762026B1 (https=)
JP (2) JP7426940B2 (https=)
KR (1) KR20200129127A (https=)
CN (1) CN113015543A (https=)
AU (1) AU2019231703A1 (https=)
CA (1) CA3092936A1 (https=)
IL (1) IL277127B2 (https=)
MX (1) MX2020009246A (https=)
TW (2) TW201945401A (https=)
WO (1) WO2019173530A1 (https=)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN118116596A (zh) * 2024-04-25 2024-05-31 青岛宝迈得生物科技有限公司 基于大数据分析的肝胆与心血管疾病共发风险评估方法
CN121015868A (zh) * 2025-10-29 2025-11-28 核工业四一六医院 Pcsk9抑制剂在制备用于治疗甲减伴高脂血症的药物中的应用

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9402707B2 (en) 2008-07-22 2016-08-02 Neuravi Limited Clot capture systems and associated methods
JO3672B1 (ar) 2008-12-15 2020-08-27 Regeneron Pharma أجسام مضادة بشرية عالية التفاعل الكيماوي بالنسبة لإنزيم سبتيليسين كنفرتيز بروبروتين / كيكسين نوع 9 (pcsk9).
WO2012052982A1 (en) 2010-10-22 2012-04-26 Neuravi Limited Clot engagement and removal system
PL3395836T3 (pl) 2011-01-28 2021-12-13 Sanofi Biotechnology Ludzkie przeciwciała przeciwko pcsk9 do zastosowania w sposobach leczenia konkretnych grup osobników
ES3029850T3 (en) 2011-03-09 2025-06-25 Neuravi Ltd A clot retrieval device for removing occlusive clot from a blood vessel
US12076037B2 (en) 2011-03-09 2024-09-03 Neuravi Limited Systems and methods to restore perfusion to a vessel
AR087305A1 (es) 2011-07-28 2014-03-12 Regeneron Pharma Formulaciones estabilizadas que contienen anticuerpos anti-pcsk9, metodo de preparacion y kit
US9433429B2 (en) 2013-03-14 2016-09-06 Neuravi Limited Clot retrieval devices
SI2967610T1 (sl) 2013-03-14 2019-07-31 Neuravi Limited Naprava za odkrivanje strdka za odstranjevanje okluzivnega strdka in krvne žile
EP2967611B1 (en) 2013-03-14 2019-01-16 Neuravi Limited Devices for removal of acute blockages from blood vessels
MX2016006226A (es) 2013-11-12 2016-09-07 Sanofi Biotechnology Regimenes de dosificacion para uso con inhibidores de pcsk9.
US11253278B2 (en) 2014-11-26 2022-02-22 Neuravi Limited Clot retrieval system for removing occlusive clot from a blood vessel
EP3223723B1 (en) 2014-11-26 2020-01-08 Neuravi Limited A clot retrieval device for removing occlusive clot from a blood vessel
US10617435B2 (en) 2014-11-26 2020-04-14 Neuravi Limited Clot retrieval device for removing clot from a blood vessel
JP2018523684A (ja) 2015-08-18 2018-08-23 リジェネロン・ファーマシューティカルズ・インコーポレイテッドＲｅｇｅｎｅｒｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． リポタンパク質アフェレーシスを受けている高脂血症の患者を治療するための抗ｐｃｓｋ９阻害抗体
KR102494176B1 (ko) 2016-09-06 2023-02-02 뉴라비 리미티드 혈관으로부터 폐색 혈전을 제거하기 위한 혈전 회수 장치
US10842498B2 (en) * 2018-09-13 2020-11-24 Neuravi Limited Systems and methods of restoring perfusion to a vessel
US11406416B2 (en) 2018-10-02 2022-08-09 Neuravi Limited Joint assembly for vasculature obstruction capture device
TWI759867B (zh) * 2019-09-19 2022-04-01 大陸商信達生物製藥（蘇州）有限公司 抗前蛋白轉化酶枯草桿菌蛋白酶／ｋｅｘｉｎ型９抗體用於製備治療膽固醇相關疾病之藥物的用途
US11712231B2 (en) 2019-10-29 2023-08-01 Neuravi Limited Proximal locking assembly design for dual stent mechanical thrombectomy device
US11517340B2 (en) 2019-12-03 2022-12-06 Neuravi Limited Stentriever devices for removing an occlusive clot from a vessel and methods thereof
US11717308B2 (en) 2020-04-17 2023-08-08 Neuravi Limited Clot retrieval device for removing heterogeneous clots from a blood vessel
US11871946B2 (en) 2020-04-17 2024-01-16 Neuravi Limited Clot retrieval device for removing clot from a blood vessel
US11730501B2 (en) 2020-04-17 2023-08-22 Neuravi Limited Floating clot retrieval device for removing clots from a blood vessel
US11737771B2 (en) 2020-06-18 2023-08-29 Neuravi Limited Dual channel thrombectomy device
US11937836B2 (en) 2020-06-22 2024-03-26 Neuravi Limited Clot retrieval system with expandable clot engaging framework
US11439418B2 (en) 2020-06-23 2022-09-13 Neuravi Limited Clot retrieval device for removing clot from a blood vessel
US11395669B2 (en) 2020-06-23 2022-07-26 Neuravi Limited Clot retrieval device with flexible collapsible frame
US11864781B2 (en) 2020-09-23 2024-01-09 Neuravi Limited Rotating frame thrombectomy device
US11937837B2 (en) 2020-12-29 2024-03-26 Neuravi Limited Fibrin rich / soft clot mechanical thrombectomy device
US12029442B2 (en) 2021-01-14 2024-07-09 Neuravi Limited Systems and methods for a dual elongated member clot retrieval apparatus
US12064130B2 (en) 2021-03-18 2024-08-20 Neuravi Limited Vascular obstruction retrieval device having sliding cages pinch mechanism
US11974764B2 (en) 2021-06-04 2024-05-07 Neuravi Limited Self-orienting rotating stentriever pinching cells
CN115413625A (zh) * 2022-08-22 2022-12-02 郑咏秋 一种类风湿性冠心病动物模型及其构建方法和应用

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104582698A (zh) * 2012-06-29 2015-04-29 阿玛林制药爱尔兰有限公司 在接受抑制素治疗的受试者中降低心血管事件风险的方法
CN105814085A (zh) * 2013-10-11 2016-07-27 赛诺菲生物技术公司 Pcsk9抑制剂用于治疗高血脂症的用途
US20170049886A1 (en) * 2015-08-18 2017-02-23 Regeneron Pharmaceuticals, Inc. Methods for reducing or eliminating the need for lipoprotein apheresis in patients with hyperlipidemia by administering a pcsk9 inhibitor
CN106794244A (zh) * 2014-03-17 2017-05-31 赛诺菲生物技术公司 用于降低心血管风险的方法
CN107106678A (zh) * 2014-07-16 2017-08-29 赛诺菲生物技术公司 用于治疗患有高胆固醇血症的高心血管风险患者的方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
JO3672B1 (ar) 2008-12-15 2020-08-27 Regeneron Pharma أجسام مضادة بشرية عالية التفاعل الكيماوي بالنسبة لإنزيم سبتيليسين كنفرتيز بروبروتين / كيكسين نوع 9 (pcsk9).
PL3395836T3 (pl) 2011-01-28 2021-12-13 Sanofi Biotechnology Ludzkie przeciwciała przeciwko pcsk9 do zastosowania w sposobach leczenia konkretnych grup osobników
WO2012168491A1 (en) 2011-06-10 2012-12-13 Novartis Ag Pharmaceutical formulations of pcsk9 antagonists
AR087305A1 (es) 2011-07-28 2014-03-12 Regeneron Pharma Formulaciones estabilizadas que contienen anticuerpos anti-pcsk9, metodo de preparacion y kit
ES2992345T3 (es) 2011-09-16 2024-12-11 Regeneron Pharma Métodos para reducir los niveles de lipoproteína(a) mediante la administración de un inhibidor de la proproteína convertasa subtilisina kexina-9 (PCSK9)
EA039663B1 (ru) 2012-05-03 2022-02-24 Амген Инк. Применение антитела против pcsk9 для снижения сывороточного холестерина лпнп и лечения связанных с холестерином расстройств

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104582698A (zh) * 2012-06-29 2015-04-29 阿玛林制药爱尔兰有限公司 在接受抑制素治疗的受试者中降低心血管事件风险的方法
CN105814085A (zh) * 2013-10-11 2016-07-27 赛诺菲生物技术公司 Pcsk9抑制剂用于治疗高血脂症的用途
CN106794244A (zh) * 2014-03-17 2017-05-31 赛诺菲生物技术公司 用于降低心血管风险的方法
CN107106678A (zh) * 2014-07-16 2017-08-29 赛诺菲生物技术公司 用于治疗患有高胆固醇血症的高心血管风险患者的方法
US20170049886A1 (en) * 2015-08-18 2017-02-23 Regeneron Pharmaceuticals, Inc. Methods for reducing or eliminating the need for lipoprotein apheresis in patients with hyperlipidemia by administering a pcsk9 inhibitor

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN118116596A (zh) * 2024-04-25 2024-05-31 青岛宝迈得生物科技有限公司 基于大数据分析的肝胆与心血管疾病共发风险评估方法
CN118116596B (zh) * 2024-04-25 2024-07-02 青岛宝迈得生物科技有限公司 基于大数据分析的肝胆与心血管疾病共发风险评估方法
CN121015868A (zh) * 2025-10-29 2025-11-28 核工业四一六医院 Pcsk9抑制剂在制备用于治疗甲减伴高脂血症的药物中的应用

Also Published As

Publication number Publication date
JP2024028919A (ja) 2024-03-05
KR20200129127A (ko) 2020-11-17
EP3762026A1 (en) 2021-01-13
WO2019173530A1 (en) 2019-09-12
IL277127B1 (en) 2025-07-01
CA3092936A1 (en) 2019-09-12
TW202521589A (zh) 2025-06-01
US20190292273A1 (en) 2019-09-26
RU2020132463A (ru) 2022-04-06
IL277127B2 (en) 2025-11-01
TW201945401A (zh) 2019-12-01
IL277127A (en) 2020-10-29
MX2020009246A (es) 2021-01-15
JP7426940B2 (ja) 2024-02-02
AU2019231703A1 (en) 2020-10-22
JP2021515772A (ja) 2021-06-24
EP3762026B1 (en) 2026-04-08

Similar Documents

Publication Publication Date Title
CN113015543A (zh) Pcsk9抑制剂用于降低心血管风险的用途
JP6964090B2 (ja) Ａｎｇｐｔｌ８阻害剤およびａｎｇｐｔｌ３阻害剤を用いて高脂血症を処置するための方法
JP2024147744A (ja) 心血管リスクを低減させる方法
US20240261400A1 (en) Methods for reducing or eliminating the need for lipoprotein apheresis in patients with hyperlipidemia by administering alirocumab
JP6912374B2 (ja) 高コレステロール血症を有する高心血管リスク患者を処置するための方法
CN115154599A (zh) Pcsk9抑制剂用于治疗高血脂症的用途
KR20240017117A (ko) 이형접합성 가족성 고콜레스테롤혈증(heFH) 환자의 치료방법
CN115427450A (zh) 通过施用il-4r拮抗剂治疗特应性皮炎的方法
US20180237513A1 (en) Method of treating or preventing stroke
JP2023506732A (ja) ホモ接合型家族性高コレステロール血症を処置するためのｐｃｓｋ９阻害剤の使用
RU2837845C2 (ru) Применение ингибитора pcsk9 для снижения сердечно-сосудистого риска
EA040479B1 (ru) Способы лечения гиперлипидемии ингибитором angptl8 и ингибитором angptl3

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination